Free Trial

Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Veracyte logo with Medical background

Sumitomo Mitsui Trust Group Inc. decreased its position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 9.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 2,263,939 shares of the biotechnology company's stock after selling 229,438 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 2.90% of Veracyte worth $67,126,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in VCYT. Jones Financial Companies Lllp raised its holdings in shares of Veracyte by 49.7% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 237 shares during the last quarter. Versant Capital Management Inc increased its holdings in shares of Veracyte by 1,267.6% in the 1st quarter. Versant Capital Management Inc now owns 930 shares of the biotechnology company's stock worth $28,000 after buying an additional 862 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Veracyte during the 4th quarter worth approximately $64,000. US Bancorp DE lifted its holdings in Veracyte by 57.4% during the 4th quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company's stock valued at $70,000 after buying an additional 647 shares in the last quarter. Finally, Sterling Capital Management LLC lifted its stake in Veracyte by 810.2% in the fourth quarter. Sterling Capital Management LLC now owns 2,421 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 2,155 shares during the period.

Veracyte Stock Performance

NASDAQ VCYT traded down $0.07 on Friday, reaching $27.51. The stock had a trading volume of 445,469 shares, compared to its average volume of 916,372. The stock has a market cap of $2.15 billion, a P/E ratio of 67.10 and a beta of 2.07. Veracyte, Inc. has a 12-month low of $19.73 and a 12-month high of $47.32. The business's 50-day moving average price is $28.10 and its 200 day moving average price is $33.85.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on VCYT. Wall Street Zen cut Veracyte from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th. Guggenheim reduced their target price on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. UBS Group dropped their price target on Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Needham & Company LLC cut their price objective on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Finally, Stephens reaffirmed an "overweight" rating and set a $45.00 target price on shares of Veracyte in a research note on Wednesday, March 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $40.90.

View Our Latest Report on Veracyte

Veracyte Company Profile

(Free Report)

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.

Read More

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Should You Invest $1,000 in Veracyte Right Now?

Before you consider Veracyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veracyte wasn't on the list.

While Veracyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

AI Stocks Are Printing Money — These 3 Are Just Getting Started
Why Drone Stocks Are Skyrocketing Right Now!
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines